Biology subjects

McMullen, T. P.

Publications and source records attributed to McMullen, T. P..

4 recordsLinked to original sources

bioRxiv2026

Restoration of deficient IL-15 signaling enhances innate lymphoid cell immunity in brain metastasis

Natural killer (NK) cells and type 1 innate lymphoid cells (ILC1s), collectively known as group 1 innate lymphoid cells (ILCs), are critical mediators of anti-tumor immunity, yet their role in brain metastasis remains poorly defined. Using single-cell RNA sequencing and functional depletion models, we show that group 1 ILCs fail to provide adequate tumor control in breast cancer brain metastasis (BCBM). In contrast to the liver, where diverse, functionally competent group 1 ILC populations facilitate excellent metastatic control, group 1 ILCs in BCBM show limited diversity and profound tissue-specific dysfunction such that their depletion had no effect on tumor burden despite modest parenchymal infiltration. We attribute this group 1 ILC dysfunction to severely restricted IL-15 availability, with IL-15R protein detected at 500-fold lower concentration in the brain than in the liver. Local IL-15 complex administration restored group 1 ILC accumulation, cytotoxicity, and tissue residency, significantly reducing brain metastatic burden independent of T cells. Intracranial delivery of IL-15-secreting induced pluripotent stem-cell-derived (iPSC)-NK cells, already in clinical testing for non-small cell lung cancer, significantly reduced tumor burden. Collectively, these findings reveal how tissue-specific differences in cytokine availability shape group 1 ILC population diversity and disease response, establishing localized IL-15 signaling as a compelling strategy to unlock innate immunity against intracranial malignancies.

immunology↗

bioRxiv2026

Cell-of-origin shapes tumor subtype in BRCA1-associated triple-negative breast cancer

Pathogenic germline BRCA1 variants greatly increase lifetime breast cancer risk, with no targeted prevention. Accrual of mutations following DNA repair errors in luminal progenitors is considered the chief mechanism of triple-negative breast cancer (TNBC) initiation, which cannot explain the organ specificity nor the phenotypic spectrum of the disease. Here we show that TNBC also originates in basal-myoepithelial cells, and that the cell of origin shapes TNBC subtype through aberrant epithelial differentiation, likely due to pleiotropic role of BRCA1 in regulating hormone signaling. Single-cell RNA sequencing of 67,001 cells from Wap-Cre Brca1/p53 mice and reanalysis of published Blg-Cre data show that aberrant basal-myoepithelial differentiation (Wap-Cre) generates the mesenchymal subtype (TNBC-M) and aberrant luminal differentiation (Blg-Cre) the basal-like subtype (TNBC-BL1). We also show that both subtypes occur at comparable frequency in BRCA1 carriers. Aberrant basal-myoepithelial differentiation precedes tumor formation, and only tumors derived from transplanted basal cells reproduce the basal-containing phenotype of spontaneous tumors. Comparison with a developmental atlas identifies de-differentiation of myoepithelial cells into basal cells lacking myoepithelial markers, a fetal state, whereas experimental metastases shift toward luminal states while retaining a TNBC-M-like transcriptional program. These findings support the inclusion of basal-myoepithelial and luminal cells in targeted prevention strategies for BRCA1 carriers, and adoption of TNBC subtyping for patient stratification and improving outcomes.

cancer biology↗

bioRxiv2025

PHLDA2 promotes breast cancer metastasis by co-opting a developmental program for placental vascular remodeling

Identifying drivers of metastasis is essential for developing new treatments for patients with advanced disease. Here, we identify PHLDA2 as a robust driver of breast cancer metastasis. Previous work established PHLDA2 as an imprinted gene expressed by trophoblasts which are critical for vascular remodeling during placental development. We find that hypomethylation of PHLDA2 in breast tumors correlates with increased gene expression, which is associated with metastasis and poor survival in breast cancer patients. RNA-sequencing showed that PHLDA2 overexpression results in upregulation of genes that control invasion, extracellular matrix assembly, and vascular remodeling, consistent with trophoblast functions in placental development. Using an in vitro vascularized microtumor (VMT) system, we find that PHLDA2 functions through SPARC, which promotes metastasis by inducing vascular permeability and enhancing tumor dissemination. These data suggest that increased expression of PHLDA2 through hypomethylation promotes metastasis by ectopic expression of a developmental program for vascular remodeling.

cancer biology↗

bioRxiv2024

Microglia are not required for maintenance of blood-brain barrier properties in health, but PLX5622 alters brain endothelial cholesterol metabolism

Microglia are resident immune cells of the central nervous system, yet their functions far exceed those related to immunology. From pruning neural synapses during development to preventing excessive neural activity throughout life, microglia are intimately involved in the brains most basic processes. Studies have reported a close interaction between microglia and endothelial cells, as well as both helpful and harmful roles for microglia at the blood-brain barrier (BBB) in the context of disease. However, much less work has been done to understand microglia-endothelial cell interactions in the healthy brain. Here, we aim to determine the role of microglia at the healthy BBB. We used the colony-stimulating factor 1 receptor (CSF1R) inhibitor PLX5622 to deplete microglia and analyzed BBB ultrastructure, permeability, and transcriptome. Interestingly, we found that, despite their direct contact with endothelial cells, microglia are not necessary for maintenance of BBB structure, function, or gene expression in the healthy brain. However, we found that PLX5622 treatment alters brain endothelial cholesterol metabolism, and this effect was independent from microglial depletion, suggesting PLX5622 has off-target effects on brain vasculature.

neuroscience↗